Zepbound versus Wegovy

In this episode of the Docs Who Lift podcast, Dr. Spencer Nadolsky and Dr. Karl discuss the latest findings from the SURMOUNT-5 on Zepbound (tirzepatide) vs. Wegovy (semaglutide,) two leading medications for weight loss and type 2 diabetes. They explore the efficacy, safety, and cost-effectiveness of these drugs, highlighting the significant weight loss outcomes associated with tirzepatide compared to semaglutide. The conversation also delves into the importance of patient stewardship in prescribing these medications, the impact of gender differences on weight loss results, and the need for more affordable options in the market.